ZA200309599B - Method of selecting DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription representing activity - Google Patents
Method of selecting DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription representing activity Download PDFInfo
- Publication number
- ZA200309599B ZA200309599B ZA200309599A ZA200309599A ZA200309599B ZA 200309599 B ZA200309599 B ZA 200309599B ZA 200309599 A ZA200309599 A ZA 200309599A ZA 200309599 A ZA200309599 A ZA 200309599A ZA 200309599 B ZA200309599 B ZA 200309599B
- Authority
- ZA
- South Africa
- Prior art keywords
- sequence
- star
- gene
- dna
- sequences
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 317
- 238000013518 transcription Methods 0.000 title claims description 211
- 230000035897 transcription Effects 0.000 title claims description 200
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 131
- 230000000694 effects Effects 0.000 title claims description 114
- 238000000034 method Methods 0.000 title claims description 104
- 239000013598 vector Substances 0.000 title description 74
- 210000004027 cell Anatomy 0.000 claims description 214
- 230000014509 gene expression Effects 0.000 claims description 175
- 108020004414 DNA Proteins 0.000 claims description 147
- 239000013612 plasmid Substances 0.000 claims description 138
- 239000012634 fragment Substances 0.000 claims description 91
- 108700008625 Reporter Genes Proteins 0.000 claims description 79
- 150000007523 nucleic acids Chemical group 0.000 claims description 58
- 238000004458 analytical method Methods 0.000 claims description 53
- 108010084455 Zeocin Proteins 0.000 claims description 50
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims description 50
- 238000012360 testing method Methods 0.000 claims description 50
- 210000000349 chromosome Anatomy 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 230000001105 regulatory effect Effects 0.000 claims description 35
- 241000196324 Embryophyta Species 0.000 claims description 28
- 229960003722 doxycycline Drugs 0.000 claims description 26
- 241000894007 species Species 0.000 claims description 25
- 238000012549 training Methods 0.000 claims description 17
- 108020004511 Recombinant DNA Proteins 0.000 claims description 15
- 108020001507 fusion proteins Proteins 0.000 claims description 14
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 201000008968 osteosarcoma Diseases 0.000 claims description 13
- 230000002103 transcriptional effect Effects 0.000 claims description 12
- 101710196632 LexA repressor Proteins 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 230000004568 DNA-binding Effects 0.000 claims description 8
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 101000669028 Homo sapiens Zinc phosphodiesterase ELAC protein 2 Proteins 0.000 claims description 6
- 102100039877 Zinc phosphodiesterase ELAC protein 2 Human genes 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 238000010353 genetic engineering Methods 0.000 claims description 3
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 5
- 108060001084 Luciferase Proteins 0.000 description 76
- 239000005089 Luciferase Substances 0.000 description 74
- 230000000754 repressing effect Effects 0.000 description 60
- 102000004169 proteins and genes Human genes 0.000 description 58
- 230000006870 function Effects 0.000 description 45
- 108700019146 Transgenes Proteins 0.000 description 44
- 239000003623 enhancer Substances 0.000 description 40
- 108091034117 Oligonucleotide Proteins 0.000 description 36
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 34
- 108010077544 Chromatin Proteins 0.000 description 33
- 210000003483 chromatin Anatomy 0.000 description 33
- 239000000047 product Substances 0.000 description 24
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 23
- 238000003556 assay Methods 0.000 description 23
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 230000030279 gene silencing Effects 0.000 description 22
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 21
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 19
- 230000027455 binding Effects 0.000 description 19
- 230000003115 biocidal effect Effects 0.000 description 19
- 238000010367 cloning Methods 0.000 description 19
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 18
- 241000219194 Arabidopsis Species 0.000 description 17
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 17
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 17
- 239000005090 green fluorescent protein Substances 0.000 description 17
- 229950010131 puromycin Drugs 0.000 description 17
- 108091035710 E-box Proteins 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 241000701022 Cytomegalovirus Species 0.000 description 15
- 230000002559 cytogenic effect Effects 0.000 description 13
- 230000009261 transgenic effect Effects 0.000 description 13
- 108091035707 Consensus sequence Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- 101150076274 upp gene Proteins 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 101100383920 Fragaria ananassa MCSI gene Proteins 0.000 description 11
- 108010047956 Nucleosomes Proteins 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000005755 formation reaction Methods 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 230000010354 integration Effects 0.000 description 11
- 210000001623 nucleosome Anatomy 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 230000032823 cell division Effects 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 10
- 229960004413 flucytosine Drugs 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 108091027981 Response element Proteins 0.000 description 9
- 239000004098 Tetracycline Substances 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229960002180 tetracycline Drugs 0.000 description 9
- 229930101283 tetracycline Natural products 0.000 description 9
- 235000019364 tetracycline Nutrition 0.000 description 9
- 150000003522 tetracyclines Chemical class 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 108010034791 Heterochromatin Proteins 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 210000004458 heterochromatin Anatomy 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010091086 Recombinases Proteins 0.000 description 7
- 102000018120 Recombinases Human genes 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 102000049867 Steroidogenic acute regulatory protein Human genes 0.000 description 6
- 108010018411 Steroidogenic acute regulatory protein Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000012226 gene silencing method Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 239000011269 tar Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 241001539176 Hime Species 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 230000006195 histone acetylation Effects 0.000 description 5
- 210000003917 human chromosome Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 4
- 108010022894 Euchromatin Proteins 0.000 description 4
- 108010046276 FLP recombinase Proteins 0.000 description 4
- 102100039869 Histone H2B type F-S Human genes 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 4
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 210000000632 euchromatin Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000012212 insulator Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 102000031635 methyl-CpG binding proteins Human genes 0.000 description 4
- 108091009877 methyl-CpG binding proteins Proteins 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 102000000311 Cytosine Deaminase Human genes 0.000 description 3
- 108010080611 Cytosine Deaminase Proteins 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 108700005087 Homeobox Genes Proteins 0.000 description 3
- 101100311234 Oryza sativa subsp. japonica STAR1 gene Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 101100235354 Pseudomonas putida (strain ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950 / KT2440) lexA1 gene Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000007622 bioinformatic analysis Methods 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 108091006090 chromatin-associated proteins Proteins 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000012411 cloning technique Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000012248 genetic selection Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 101150047523 lexA gene Proteins 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000001718 repressive effect Effects 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000037426 transcriptional repression Effects 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102100036601 Aggrecan core protein Human genes 0.000 description 2
- 241000219195 Arabidopsis thaliana Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 241001649081 Dina Species 0.000 description 2
- 101100440639 Drosophila melanogaster Cont gene Proteins 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- 102100033961 Guanylin Human genes 0.000 description 2
- 108091008054 HOXC@ Proteins 0.000 description 2
- 101000999998 Homo sapiens Aggrecan core protein Proteins 0.000 description 2
- 101001068469 Homo sapiens Guanylin Proteins 0.000 description 2
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108091036060 Linker DNA Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000019040 Nuclear Antigens Human genes 0.000 description 2
- 108010051791 Nuclear Antigens Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101710197208 Regulatory protein cro Proteins 0.000 description 2
- 102000009661 Repressor Proteins Human genes 0.000 description 2
- 108010034634 Repressor Proteins Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910052729 chemical element Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000010502 episomal replication Effects 0.000 description 2
- 241001233957 eudicotyledons Species 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FXYZDFSNBBOHTA-UHFFFAOYSA-N 2-[amino(morpholin-4-ium-4-ylidene)methyl]guanidine;chloride Chemical compound Cl.NC(N)=NC(=N)N1CCOCC1 FXYZDFSNBBOHTA-UHFFFAOYSA-N 0.000 description 1
- UHFICAKXFHFOCN-UHFFFAOYSA-N 6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-carboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(C=3C=C4C(C)(C)CCC(C4=CC=3)(C)C)=CC=C21 UHFICAKXFHFOCN-UHFFFAOYSA-N 0.000 description 1
- 102100022094 Acid-sensing ion channel 2 Human genes 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
- 101710094856 Apoptin Proteins 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 240000001546 Byrsonima crassifolia Species 0.000 description 1
- 235000003197 Byrsonima crassifolia Nutrition 0.000 description 1
- 101100535994 Caenorhabditis elegans tars-1 gene Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 101150065984 Comp gene Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100108071 Dictyostelium discoideum act10 gene Proteins 0.000 description 1
- 108700020787 Drosophila Pc Proteins 0.000 description 1
- 101100316028 Drosophila melanogaster Uggt gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 102100021086 Homeobox protein Hox-D4 Human genes 0.000 description 1
- 102100034858 Homeobox protein Hox-D8 Human genes 0.000 description 1
- 101000901079 Homo sapiens Acid-sensing ion channel 2 Proteins 0.000 description 1
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 1
- 101001041136 Homo sapiens Homeobox protein Hox-D4 Proteins 0.000 description 1
- 101001019776 Homo sapiens Homeobox protein Hox-D8 Proteins 0.000 description 1
- 101001139112 Homo sapiens Krueppel-like factor 9 Proteins 0.000 description 1
- 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102100020684 Krueppel-like factor 9 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 1
- 108091008758 NR0A5 Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101100311235 Oryza sativa subsp. japonica STAR2 gene Proteins 0.000 description 1
- 101150102573 PCR1 gene Proteins 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100028840 Proline-rich transmembrane protein 2 Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101100061047 Rhodobacter capsulatus ctaD gene Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100076570 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MER1 gene Proteins 0.000 description 1
- 101100473039 Schistocerca americana HNRNP gene Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100024687 Zinc finger protein 2 Human genes 0.000 description 1
- 101710180929 Zinc finger protein 2 Proteins 0.000 description 1
- VOGVEUAIIKVAOE-VEECZQFMSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-6-chloro-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-ol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21.C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 VOGVEUAIIKVAOE-VEECZQFMSA-N 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- QLDHWVVRQCGZLE-UHFFFAOYSA-N acetyl cyanide Chemical compound CC(=O)C#N QLDHWVVRQCGZLE-UHFFFAOYSA-N 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 102000008273 histone deacetylase activity proteins Human genes 0.000 description 1
- 108040002983 histone deacetylase activity proteins Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- NVGOPFQZYCNLDU-UHFFFAOYSA-N norflurazon Chemical compound O=C1C(Cl)=C(NC)C=NN1C1=CC=CC(C(F)(F)F)=C1 NVGOPFQZYCNLDU-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01202581A EP1273666A1 (en) | 2001-07-04 | 2001-07-04 | Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity |
| US30319901P | 2001-07-05 | 2001-07-05 | |
| US10/190,312 US7192741B2 (en) | 2001-07-04 | 2002-07-05 | DNA sequences comprising gene transcription regulatory qualities and methods for detecting and using such DNA sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200309599B true ZA200309599B (en) | 2006-05-31 |
Family
ID=47915807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200309599A ZA200309599B (en) | 2001-07-04 | 2003-12-10 | Method of selecting DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription representing activity |
Country Status (22)
| Country | Link |
|---|---|
| US (9) | US7192741B2 (no) |
| EP (8) | EP1808488B1 (no) |
| JP (3) | JP4500044B2 (no) |
| KR (2) | KR100942117B1 (no) |
| CN (1) | CN1266282C (no) |
| AT (8) | ATE466941T1 (no) |
| AU (3) | AU2002314629B2 (no) |
| BR (1) | BRPI0210771B8 (no) |
| CA (2) | CA2450020C (no) |
| CY (1) | CY1107678T1 (no) |
| DE (8) | DE60236379D1 (no) |
| DK (8) | DK1845162T3 (no) |
| ES (8) | ES2274045T3 (no) |
| HK (1) | HK1068652A1 (no) |
| IL (4) | IL159674A0 (no) |
| MX (1) | MXPA03011801A (no) |
| NO (1) | NO338477B1 (no) |
| NZ (1) | NZ530218A (no) |
| PT (1) | PT1600510E (no) |
| SG (1) | SG143066A1 (no) |
| WO (1) | WO2003004704A2 (no) |
| ZA (1) | ZA200309599B (no) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1600510E (pt) | 2001-07-04 | 2007-06-25 | Chromagenics Bv | Sequências de adn com actividade anti-repressora. |
| WO2003106674A2 (en) * | 2002-06-14 | 2003-12-24 | Chromagenics B.V. | Means and methods for regulating gene expression |
| ATE500331T1 (de) | 2002-06-14 | 2011-03-15 | Chromagenics Bv | Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden |
| ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| CA2510179C (en) | 2002-12-18 | 2013-04-23 | Chromagenics B.V. | A method for improving protein production |
| DE60312039T2 (de) | 2002-12-20 | 2007-11-08 | Chromagenics B.V. | Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| CN1863918B (zh) | 2003-10-02 | 2011-03-30 | 克鲁塞尔荷兰公司 | 用于重组腺病毒的包装细胞 |
| WO2005059149A2 (en) * | 2003-12-12 | 2005-06-30 | Chromagenics B.V. | Improved protein production |
| CA2554054C (en) | 2004-01-20 | 2013-06-04 | Merus B.V. | Mixtures of binding proteins |
| PT1763586E (pt) | 2004-07-08 | 2008-02-25 | Chromagenics Bv | Nova sequência para melhorar a expressão de ácido nucleico |
| ATE459720T1 (de) * | 2004-08-18 | 2010-03-15 | Bayer Cropscience Ag | Pflanzen mit erhöhter plastidär aktivität der stärkephosphorylierenden r3-enzyme |
| SI1809750T1 (sl) | 2004-11-08 | 2012-08-31 | Chromagenics Bv | Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina |
| AU2005300503B2 (en) | 2004-11-08 | 2010-12-16 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| US20060195935A1 (en) * | 2004-11-08 | 2006-08-31 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| US8999667B2 (en) | 2004-11-08 | 2015-04-07 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| US20100136616A1 (en) * | 2004-11-08 | 2010-06-03 | Chromagenics B.V. | Selection of Host Cells Expressing Protein at High Levels |
| US8039230B2 (en) | 2004-11-08 | 2011-10-18 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| CA2587712C (en) * | 2004-11-18 | 2013-02-12 | National University Of Corporation Hiroshima University | Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant |
| WO2007107578A1 (en) | 2006-03-20 | 2007-09-27 | Chromagenics B.V. | Expression augmenting dna fragments, use thereof, and methods for finding thereof |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| JP2010515435A (ja) * | 2007-01-08 | 2010-05-13 | ミリポア・コーポレイション | 遺伝子増幅を不要とする高発現細胞株 |
| DK2443239T3 (en) | 2009-06-15 | 2016-02-15 | Cellagenics B V | New stringent selection markers |
| US8566596B2 (en) | 2010-08-24 | 2013-10-22 | Cisco Technology, Inc. | Pre-association mechanism to provide detailed description of wireless services |
| EP2611915B1 (en) | 2010-09-01 | 2015-04-15 | Cellagenics B.V. | Nucleic acid fragments from a ribosomal protein promoter for enhancing gene expression |
| KR102382304B1 (ko) | 2012-04-20 | 2022-04-04 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| CN105051066B (zh) | 2012-09-27 | 2019-08-06 | 美勒斯公司 | 作为T细胞衔接器的双特异性IgG抗体 |
| US10417380B1 (en) | 2013-12-31 | 2019-09-17 | Mckesson Corporation | Systems and methods for determining and communicating a prescription benefit coverage denial to a prescriber |
| US10489552B2 (en) | 2014-02-14 | 2019-11-26 | Mckesson Corporation | Systems and methods for determining and communicating patient incentive information to a prescriber |
| SI3110849T1 (sl) | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
| AU2015223566B2 (en) | 2014-02-28 | 2020-10-08 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| US10157262B1 (en) | 2015-03-10 | 2018-12-18 | Mckesson Corporation | Systems and methods for determining patient financial responsibility for multiple prescription products |
| LT3115376T (lt) | 2015-07-10 | 2018-11-12 | Merus N.V. | Antikūnai, kurie jungiasi su žmogaus cd3 |
| SI3365373T1 (sl) | 2015-10-23 | 2021-08-31 | Merus N.V. | Vezne molekule, ki zaviranjo rast raka |
| US11514137B1 (en) | 2016-03-30 | 2022-11-29 | Mckesson Corporation | Alternative therapy identification system |
| US10999224B1 (en) | 2017-02-01 | 2021-05-04 | Mckesson Corporation | Method and apparatus for parsing an electronic message and constructing multiple differently prioritized messages therefrom |
| WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
| US10862832B1 (en) | 2018-07-24 | 2020-12-08 | Mckesson Corporation | Computing system and method for automatically reversing an action indicated by an electronic message |
| US11043437B2 (en) | 2019-01-07 | 2021-06-22 | Applied Materials, Inc. | Transparent substrate with light blocking edge exclusion zone |
| US11636548B1 (en) | 2019-06-26 | 2023-04-25 | Mckesson Corporation | Method, apparatus, and computer program product for providing estimated prescription costs |
| US11562437B1 (en) | 2019-06-26 | 2023-01-24 | Mckesson Corporation | Method, apparatus, and computer program product for providing estimated prescription costs |
| EP3772518A1 (en) | 2019-08-07 | 2021-02-10 | Merus N.V. | Modified human variable domains |
| US20230104317A1 (en) * | 2020-01-31 | 2023-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods to Identify Genetic Silencers and Applications Thereof |
| US11610240B1 (en) | 2020-02-17 | 2023-03-21 | Mckesson Corporation | Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction |
| CA3175227A1 (en) | 2020-05-21 | 2021-11-25 | Cornelis De Kruif | Methods and means for the production of ig-like molecules |
| US11587657B2 (en) | 2020-09-04 | 2023-02-21 | Mckesson Corporation | Method, apparatus, and computer program product for performing an alternative evaluation procedure in response to an electronic message |
| CN113539357B (zh) * | 2021-06-10 | 2024-04-30 | 阿里巴巴达摩院(杭州)科技有限公司 | 基因检测方法、模型训练方法、装置、设备及系统 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US719271A (en) * | 1902-01-13 | 1903-01-27 | Solomon P Smith | Furnace. |
| US5610053A (en) | 1993-04-07 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
| US5972605A (en) * | 1994-07-07 | 1999-10-26 | Geron Corporation | Assays for regulators of mammalian telomerase expression |
| WO1996030522A1 (fr) * | 1995-03-24 | 1996-10-03 | Shionogi & Co., Ltd. | Molecule d'adn relative a la suppression d'une expression genique et nouvelle proteine |
| DE19539493A1 (de) * | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5773695A (en) | 1996-01-26 | 1998-06-30 | North Carolina State University | Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells |
| US6037525A (en) * | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| MXPA01000830A (es) | 1998-07-21 | 2002-06-04 | Cobra Therapeutics Ltd | Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina. |
| ES2292251T3 (es) | 1998-08-14 | 2008-03-01 | Chromagenics B.V. | Procedimiento de deteccion de una secuencia de adn, procedimiento de preparacion de una construccion de adn y uso de los mismos. |
| US6521419B1 (en) | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6395549B1 (en) | 1998-10-22 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors |
| NZ529329A (en) * | 1999-08-25 | 2005-06-24 | Immunex Corp | Compositions and methods for improved cell culture |
| US6586205B1 (en) | 2000-02-11 | 2003-07-01 | Millennium Pharmaceuticals, Inc. | 43239 a novel GPCR-like molecule and uses thereof |
| AU2001238178A1 (en) | 2000-02-11 | 2001-08-20 | Millennium Pharmaceuticals, Inc. | Seven-transmembrane proteins/g-protein coupled receptors |
| KR20030051662A (ko) | 2000-09-20 | 2003-06-25 | 엠엘 래보러토리즈 피엘씨 | 폴리뉴클레오티드 |
| PT1600510E (pt) | 2001-07-04 | 2007-06-25 | Chromagenics Bv | Sequências de adn com actividade anti-repressora. |
| EP1273666A1 (en) | 2001-07-04 | 2003-01-08 | Chromagenics B.V. | Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity |
| WO2003106674A2 (en) | 2002-06-14 | 2003-12-24 | Chromagenics B.V. | Means and methods for regulating gene expression |
| ATE500331T1 (de) * | 2002-06-14 | 2011-03-15 | Chromagenics Bv | Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden |
| CA2510179C (en) | 2002-12-18 | 2013-04-23 | Chromagenics B.V. | A method for improving protein production |
| DE60312039T2 (de) | 2002-12-20 | 2007-11-08 | Chromagenics B.V. | Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können |
-
2002
- 2002-06-14 PT PT05076209T patent/PT1600510E/pt unknown
- 2002-06-14 DK DK06124481.0T patent/DK1845162T3/da active
- 2002-06-14 DE DE60236379T patent/DE60236379D1/de not_active Expired - Lifetime
- 2002-06-14 AT AT06124470T patent/ATE466941T1/de active
- 2002-06-14 ES ES02741531T patent/ES2274045T3/es not_active Expired - Lifetime
- 2002-06-14 DK DK06124470.3T patent/DK1806407T3/da active
- 2002-06-14 EP EP06124465A patent/EP1808488B1/en not_active Expired - Lifetime
- 2002-06-14 AT AT06124481T patent/ATE466944T1/de active
- 2002-06-14 AT AT06124491T patent/ATE466943T1/de active
- 2002-06-14 DK DK06124475.2T patent/DK1829971T3/da active
- 2002-06-14 AT AT06124475T patent/ATE466942T1/de active
- 2002-06-14 DE DE60236331T patent/DE60236331D1/de not_active Expired - Lifetime
- 2002-06-14 AT AT06124482T patent/ATE467682T1/de active
- 2002-06-14 AT AT05076209T patent/ATE358183T1/de active
- 2002-06-14 DE DE60215502T patent/DE60215502T2/de not_active Expired - Lifetime
- 2002-06-14 DK DK06124465.3T patent/DK1808488T3/da active
- 2002-06-14 EP EP06124482A patent/EP1829972B1/en not_active Expired - Lifetime
- 2002-06-14 ES ES05076209T patent/ES2285630T3/es not_active Expired - Lifetime
- 2002-06-14 NZ NZ530218A patent/NZ530218A/en not_active IP Right Cessation
- 2002-06-14 BR BRPI0210771A patent/BRPI0210771B8/pt not_active IP Right Cessation
- 2002-06-14 KR KR1020097003929A patent/KR100942117B1/ko active IP Right Grant
- 2002-06-14 KR KR1020097003928A patent/KR100942116B1/ko active IP Right Grant
- 2002-06-14 JP JP2003510461A patent/JP4500044B2/ja not_active Expired - Fee Related
- 2002-06-14 ES ES06124482T patent/ES2344073T3/es not_active Expired - Lifetime
- 2002-06-14 ES ES06124470T patent/ES2344070T3/es not_active Expired - Lifetime
- 2002-06-14 SG SG200600027-7A patent/SG143066A1/en unknown
- 2002-06-14 AT AT06124465T patent/ATE474053T1/de active
- 2002-06-14 CN CNB028135717A patent/CN1266282C/zh not_active Expired - Lifetime
- 2002-06-14 ES ES06124475T patent/ES2344071T3/es not_active Expired - Lifetime
- 2002-06-14 WO PCT/NL2002/000390 patent/WO2003004704A2/en active Application Filing
- 2002-06-14 DE DE60236332T patent/DE60236332D1/de not_active Expired - Lifetime
- 2002-06-14 EP EP05076209A patent/EP1600510B1/en not_active Expired - Lifetime
- 2002-06-14 DK DK06124482.8T patent/DK1829972T3/da active
- 2002-06-14 ES ES06124491T patent/ES2344074T3/es not_active Expired - Lifetime
- 2002-06-14 ES ES06124481T patent/ES2344072T3/es not_active Expired - Lifetime
- 2002-06-14 MX MXPA03011801A patent/MXPA03011801A/es active IP Right Grant
- 2002-06-14 DE DE60219221T patent/DE60219221T2/de not_active Expired - Lifetime
- 2002-06-14 DE DE60236334T patent/DE60236334D1/de not_active Expired - Lifetime
- 2002-06-14 ES ES06124465T patent/ES2348174T3/es not_active Expired - Lifetime
- 2002-06-14 CA CA2450020A patent/CA2450020C/en not_active Expired - Lifetime
- 2002-06-14 IL IL15967402A patent/IL159674A0/xx active IP Right Grant
- 2002-06-14 CA CA2812799A patent/CA2812799C/en not_active Expired - Lifetime
- 2002-06-14 DK DK05076209T patent/DK1600510T3/da active
- 2002-06-14 EP EP06124475A patent/EP1829971B1/en not_active Expired - Lifetime
- 2002-06-14 DK DK02741531T patent/DK1404872T3/da active
- 2002-06-14 AT AT02741531T patent/ATE343004T1/de active
- 2002-06-14 DK DK06124491.9T patent/DK1842919T3/da active
- 2002-06-14 DE DE60236333T patent/DE60236333D1/de not_active Expired - Lifetime
- 2002-06-14 EP EP06124491A patent/EP1842919B1/en not_active Expired - Lifetime
- 2002-06-14 DE DE60237048T patent/DE60237048D1/de not_active Expired - Lifetime
- 2002-06-14 EP EP06124470A patent/EP1806407B1/en not_active Expired - Lifetime
- 2002-06-14 EP EP02741531A patent/EP1404872B1/en not_active Expired - Lifetime
- 2002-06-14 EP EP06124481A patent/EP1845162B1/en not_active Expired - Lifetime
- 2002-06-14 AU AU2002314629A patent/AU2002314629B2/en not_active Expired
- 2002-07-05 US US10/190,312 patent/US7192741B2/en not_active Expired - Lifetime
-
2003
- 2003-12-10 ZA ZA200309599A patent/ZA200309599B/en unknown
-
2004
- 2004-01-01 IL IL159674A patent/IL159674A/en unknown
- 2004-01-02 NO NO20040011A patent/NO338477B1/no not_active IP Right Cessation
-
2005
- 2005-02-04 HK HK05100936A patent/HK1068652A1/xx not_active IP Right Cessation
-
2006
- 2006-10-13 US US11/580,619 patent/US7736869B2/en not_active Expired - Fee Related
- 2006-10-13 US US11/580,620 patent/US7736870B2/en not_active Expired - Fee Related
- 2006-10-13 US US11/580,644 patent/US7662591B2/en not_active Expired - Lifetime
- 2006-10-13 US US11/580,604 patent/US7659094B2/en not_active Expired - Lifetime
- 2006-10-13 US US11/580,605 patent/US7749733B2/en not_active Expired - Fee Related
- 2006-10-13 US US11/580,494 patent/US7736868B2/en not_active Expired - Fee Related
- 2006-10-13 US US11/580,760 patent/US7655441B2/en not_active Expired - Lifetime
-
2007
- 2007-01-15 US US11/653,607 patent/US7951586B2/en not_active Expired - Fee Related
- 2007-06-19 CY CY20071100805T patent/CY1107678T1/el unknown
- 2007-11-22 AU AU2007234619A patent/AU2007234619B2/en not_active Expired
-
2008
- 2008-08-11 IL IL193373A patent/IL193373A/en active IP Right Grant
- 2008-08-11 IL IL193374A patent/IL193374A/en active IP Right Grant
-
2010
- 2010-01-18 JP JP2010008591A patent/JP5014443B2/ja not_active Expired - Lifetime
- 2010-01-18 JP JP2010008592A patent/JP5014444B2/ja not_active Expired - Lifetime
-
2011
- 2011-05-11 AU AU2011202193A patent/AU2011202193B2/en not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011202193B2 (en) | DNA sequences comprising gene transcription regulatory qualities and methods for detecting and using such DNA sequences | |
| AU2002314629A1 (en) | Method of selecting DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity | |
| JP2004533262A5 (no) | ||
| CA2812821C (en) | Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences |